Moleculin Biotech Q1 2025: Cash Burn Continues
Ticker: MBRX · Form: 10-Q · Filed: May 13, 2025 · CIK: 1659617
Sentiment: neutral
Topics: 10-Q, biotech, financials, pharmaceuticals
TL;DR
Moleculin Biotech Q1 2025: Still burning cash, but has $14.1M in the bank. No revenue yet.
AI Summary
Moleculin Biotech, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company reported minimal revenue and significant operating expenses, with a net loss for the quarter. Key financial figures include $14,127,494 in cash and cash equivalents and $3,378,895 in total current assets.
Why It Matters
This filing details Moleculin Biotech's financial health and operational status for the first quarter of 2025, providing insights into their cash runway and ongoing expenses as they advance their pharmaceutical development.
Risk Assessment
Risk Level: high — The company has minimal revenue and significant operating expenses, indicating a high burn rate and reliance on future funding or product success.
Key Numbers
- $14.1M — Cash and Cash Equivalents (As of March 31, 2025, indicating liquidity.)
- $3.4M — Total Current Assets (As of March 31, 2025, reflecting short-term assets.)
- 0.001 — Revenue (Minimal reported revenue for the period, highlighting early-stage operations.)
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Date of filing
- $14,127,494 (dollar_amount) — Cash and cash equivalents as of March 31, 2025
- $3,378,895 (dollar_amount) — Total current assets as of March 31, 2025
FAQ
What was Moleculin Biotech's net loss for the first quarter of 2025?
The filing indicates a net loss for the period ending March 31, 2025, though the specific dollar amount is not explicitly stated in the provided snippet.
What is the company's fiscal year end?
Moleculin Biotech's fiscal year ends on December 31.
What is the company's primary business classification?
The company is classified under Pharmaceutical Preparations [2834].
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 13, 2025.
How much was reported for 'Accumulated Other Comprehensive Income' at the end of 2024?
The filing mentions 'AccumulatedOtherComprehensiveIncomeMember' for 2024-12-31, but the specific value is not provided in the snippet.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Moleculin Biotech, Inc. (MBRX).